Not Yet RecruitingPhase 3

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

300 participantsStarted 2025-11-01

Plain-language summary

This is a Phase 3, randomized, double-blind, active-controlled clinical trial designed to evaluate the efficacy and safety of AG2001 in patients with acute bronchitis. The primary objective is to demonstrate the superiority of AG2001 over two active comparators based on the change in Bronchitis Severity Score (BSS) at Day 4.

Who can participate

Age range19 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged ≥19 years to \<65 years old
✓. Subjects who present symptoms of Acute Bronchitis with cough and sputum symptoms within 48 hours prior the randomization visit(Visit 2) who satisfy the following
✓. Subjects who without fever(condensed body temperature standard: less than 38.5°C) prior to randomization visit(Visit 2)
✓. Subjects who present symptoms of Acute Bronchitis with cough less then 2 weeks prior to randomization visit(Visit 2)
✓. Written consent voluntarily to participate who can understand the information provided in this clinical trial

What they're measuring

Change in Bronchitis Severity Score (BSS) from Baseline to Day 4

Timeframe: Baseline to Day 4

Trial details

NCT IDNCT07198347

SponsorAhn-Gook Pharmaceuticals Co.,Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-03-31

Contact for this trial

Minjoung Choi

+821029610629 agrndct@ahn-gook.com

View on ClinicalTrials.gov More Acute Bronchitis trials